President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

In the U.S., Niktimvo will be co-commercialized by Syndax and Incyte. The Company announced Niktimvo was added to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Adani Power's power supply to Bangladesh has been reduced amid a payment dispute, with the company halving its electricity ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Looking at individual holdings, Applovin Corp. Class A (APP) accounts for about 4.39% of total assets, followed by Heico Corporation (HEI) and Incyte Corporation (INCY). The top 10 holdings account ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...